Middle East & Africa Lung Cancer Therapy Market Forecast to 2030

Middle East & Africa Lung Cancer Therapy Market Forecast to 2030

Middle East & Africa Lung Cancer Therapy Market Forecast to 2030 – Regional Analysis – By Therapy Type (Noninvasive and Minimally Invasive), Indication (Non-Small Cell Lung Cancer and Small Cell Lung Cancer), and End User (Hospitals, Oncology Clinics, Research Centers, and Others)

Send Enquiry
Item ID: BMIRE00029873 Category: Tag:

$2,485 – $3,885

Description

The Middle East & Africa lung cancer therapy market was valued at US$ 964.67 million in 2022 and is expected to reach US$ 2,116.99 million by 2030; it is estimated to grow at a CAGR of 10.3% from 2022 to 2030.

Increase in Cases of Lung Cancer Drive Middle East & Africa Lung Cancer Therapy Market

Lung cancer is among the main causes of mortality across the world. This type of cancer can be treated more effectively if it is diagnosed early. Therefore, people at a high risk of lung cancer need to undergo routine testing to detect the formation of cancerous growth inside their lungs. Globally lung cancer is the most common cancer in men and the second most common cancer in women. According to the World Health Organization (WHO), lung cancer is the leading cause of cancer-related deaths globally, in both men and women. As per the World Cancer Research Fund International, ~2.2 million new lung cancer cases were registered worldwide in 2020.

Lung cancer is among one of the main causes of mortality across the world. Lung cancer screening is a critical component of cancer prevention approaches. The prognosis of lung cancer patients is better when the disease is diagnosed early, so people at high risk of lung cancer are prompted to undergo routine checkups to detect the formation of cancerous growth in their lungs. The socioeconomic conditions, healthcare infrastructure, and methods used to provide healthcare vary greatly throughout the Middle Eastern and African nations. The prevalence of lung cancer is extremely high in these nations and is expected to keep rising in the near future. Thus, the rising incidences of lung cancer are contributing to the initiation of lung cancer therapy programs, which drive market growth. Thus, the rising incidence of lung cancer worldwide is contributing to the research and development activities for lung cancer therapy, which is, in turn, driving the market growth.

Middle East & Africa Lung Cancer Therapy Market Overview

According to the World Health Organization, the number of new cases of lung cancer in Saudi Arabia was estimated to be 1,157 in 2020. According to the National Library of Medicine, in 2022, lung cancer accounts for 3% of all newly diagnosed cancers in Saudi Arabia. The Saudi Lung Cancer Association of Saudi Thoracic Society, in coordination with The National Cancer Center, developed few guidelines to assist healthcare professionals in the country for the management of different aspects of lung cancer prevention. The program focused on the primary prevention through tobacco control was the first aspect for the government-the recommendations encouraged all healthcare professionals to screen patients for smoking and provide counseling or referral to smoking cessation programs. For early diagnosis of patients with symptoms associated with lung cancer, it is expected standard of care to investigate, test, and provide a proper plan of treatment to the patient, if found at risk. Mass screening was also conducted on patients who were at a high risk for developing lung cancer.

Middle East & Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Million)

Middle East & Africa Lung Cancer Therapy Market Segmentation

The Middle East & Africa lung cancer therapy market is segmented based on therapy type, indication, end user, and country.

Based on therapy type, the Middle East & Africa lung cancer therapy market is bifurcated into noninvasive and minimally invasive. The noninvasive segment held a larger share in 2022. The minimally invasive segment is further subsegmented into radiofrequency ablation, microwave ablation, thermal ablation, cryoablation, chemical ablation, photodynamic ablation, and others.

By indication, the Middle East & Africa lung cancer therapy market is bifurcated into non-small cell lung cancer and small cell lung cancer. The non-small cell lung cancer segment held a larger share in 2022.

By end user, the Middle East & Africa lung cancer therapy market is segmented into hospitals, oncology clinics, research centers, and others. The hospitals segment held the largest share in 2022.

Based on country, the Middle East & Africa lung cancer therapy market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa lung cancer therapy market in 2022.

Bioventus Inc, Johnson & Johnson, Medtronic Plc, Merck KGaA, Olympus Corp, RF Medical Co Ltd, and Sun Pharmaceutical Industries Ltd are some of the leading companies operating in the Middle East & Africa lung cancer therapy market.

Summary Info

Industry:

Pricing options:

, ,

Geographical coverage:

,

Year of Publication:

At 10.3% CAGR, the Middle East & Africa Lung Cancer Therapy Market is Speculated to be Worth US$ 2,116.99 Million by 2030, Says the Research Team

According to the Research Team’ research, the Middle East & Africa lung cancer therapy market was valued at US$ 964.67 million in 2022 and is expected to reach US$ 2,116.99 million by 2030, registering a CAGR of 10.3% from 2022 to 2030. Growing demand for targeted therapy and increase in cases of lung cancer are among the critical factors attributed to the Middle East & Africa lung cancer therapy market expansion.

Targeted therapy, a type of personalized medicine, is a combination of two or more drugs, designed to directly target the cancerous cells. Therapies such as ablation and chemotherapy destroy healthy cells along with infected cells, which can affect the overall patient condition. Targeted therapy is designed in a way to selectively kill cancerous cells, keeping the function of healthy cells unhampered. With recent developments in medical technologies, focus on the use of targeted therapy for the treatment of lung cancer is increasing notably. Scientists are focusing on studying lung cancer cell mutations that are responsible for driving the uncontrolled growth of cancerous cells. The companies are using biomarkers such as EGFR, ALK, ROS1, and KRAS to develop targeted therapies, which help detect the type of mutation in the cancerous cells. Thus, the increasing focus of companies on the development of targeted therapies, coupled with the growing awareness about their benefits to lung cancer patients, is expected to bring new trends in the lung cancer therapy market in the coming years.

On the contrary, high cost of lung cancer therapy hampers the growth of Middle East & Africa lung cancer therapy market.

Based on therapy type, the Middle East & Africa lung cancer therapy market is bifurcated into noninvasive and minimally invasive. The noninvasive segment held 81.3% share of the Middle East & Africa lung cancer therapy market in 2022, amassing US$ 784.27 million. It is projected to garner US$ 1,693.97 million by 2030 to expand at 10.1% CAGR during 2022-2030. The minimally invasive segment is further subsegmented into radiofrequency ablation, microwave ablation, thermal ablation, cryoablation, chemical ablation, photodynamic ablation, and others.

By indication, the Middle East & Africa lung cancer therapy market is bifurcated into non-small cell lung cancer and small cell lung cancer. The non-small cell lung cancer segment held 88.2% share of the Middle East & Africa lung cancer therapy market in 2022, amassing US$ 850.87 million. It is projected to garner US$ 1,884.27 million by 2030 to expand at 10.4% CAGR during 2022-2030.

By end user, the Middle East & Africa lung cancer therapy market is segmented into hospitals, oncology clinics, research centers, and others. The hospitals segment held 49.4% share of the Middle East & Africa lung cancer therapy market in 2022, amassing US 476.79 million. It is projected to garner US$ 1,020.80 million by 2030 to expand at 10.0% CAGR during 2022-2030.

Based on country, the Middle East & Africa lung cancer therapy market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia held 29.6% share of Middle East & Africa lung cancer therapy market in 2022, amassing US$ 285.83 million. It is projected to garner US$ 605.25 million by 2030 to expand at 9.8% CAGR during 2022-2030.

Key players operating in the Middle East & Africa lung cancer therapy market are Bioventus Inc, Johnson & Johnson, Medtronic Plc, Merck KGaA, Olympus Corp, RF Medical Co Ltd, and Sun Pharmaceutical Industries Ltd, among others.

o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa lung cancer therapy market.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in Middle East & Africa lung cancer therapy market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the lung cancer therapy market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution

TABLE OF CONTENTS

1. Introduction
1.1 the Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Middle East & Africa Lung Cancer Therapy Market, by Country
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Middle East & Africa Lung Cancer Therapy Market – Key Industry Dynamics
4.1 Market Drivers:
4.1.1 Increase in Cases of Lung Cancer
4.1.2 Government Initiatives for Screening and Treatment of Lung Cancer
4.2 Market Restraints
4.2.1 High Cost of Lung Cancer Therapy
4.2.2 Lack of Awareness Regarding the Lung Cancer Therapy:
4.3 Market Opportunities
4.3.1 Rising Number of Lung Cancer Therapy in Clinical Trials
4.4 Future Trends
4.4.1 Growing Demand for Targeted Therapy
4.5 Impact Analysis:
5. Middle East & Africa Lung Cancer Therapy Market – Global Market Analysis
5.1 Middle East & Africa Lung Cancer Therapy Market Revenue (US$ Mn), 2020 – 2030
6. Middle East & Africa Lung Cancer Therapy Market – Revenue and Forecast to 2030 – by Therapy Type
6.1 Overview
6.2 Middle East & Africa Lung Cancer Therapy Market Revenue Share, by Therapy Type, 2022 & 2030 (%)
6.3 Non-Invasive Therapy
6.3.1 Overview
6.3.2 Non-Invasive Therapy: Middle East & Africa Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Minimally Invasive
6.4.1 Overview
6.4.2 Minimally Invasive: Middle East & Africa Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
6.4.3 Middle East & Africa Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
7. Middle East & Africa Lung Cancer Therapy Market – Revenue and Forecast to 2030 – by Indication
7.1 Overview
7.2 Middle East & Africa Lung Cancer Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
7.3 Non-Small Cell Lung Cancer
7.3.1 Overview
7.3.2 Non-Small Cell Lung Cancer: Middle East & Africa Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Small Cell Lung Cancer
7.4.1 Overview
7.4.2 Small Cell Lung Cancer: Middle East & Africa Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
8. Middle East & Africa Lung Cancer Therapy Market – Revenue and Forecast to 2030 – by End User
8.1 Overview
8.2 Middle East & Africa Lung Cancer Therapy Market Revenue Share, by End User, 2022 & 2030 (%)
8.3 Hospitals
8.3.1 Overview
8.3.2 Hospitals: Middle East & Africa Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Oncology Clinics
8.4.1 Overview
8.4.2 Oncology Clinics: Middle East & Africa Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Research Centers
8.5.1 Overview
8.5.2 Research Centers: Middle East & Africa Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: Middle East & Africa Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
9. Middle East & Africa Lung Cancer Therapy Market – Country Analysis
9.1 Overview
9.1.1.1 Middle East & Africa Lung Cancer Therapy Market, by Country
9.1.1.2 Saudi Arabia
9.1.1.2.1 Overview
9.1.1.2.2 Saudi Arabia: Middle East & Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.2.3 Saudi Arabia: Middle East & Africa Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.2.3.1 Saudi Arabia: Middle East & Africa Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
9.1.1.2.4 Saudi Arabia: Middle East & Africa Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.2.5 Saudi Arabia: Middle East & Africa Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
9.1.1.3 South Africa
9.1.1.3.1 Overview
9.1.1.3.2 South Africa: Middle East & Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.3.3 South Africa: Middle East & Africa Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.3.3.1 South Africa: Middle East & Africa Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
9.1.1.3.4 South Africa: Middle East & Africa Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.3.5 South Africa: Middle East & Africa Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
9.1.1.4 UAE
9.1.1.4.1 Overview
9.1.1.4.2 UAE: Middle East & Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.4.3 UAE: Middle East & Africa Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.4.3.1 UAE: Middle East & Africa Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
9.1.1.4.4 UAE: Middle East & Africa Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.4.5 UAE: Middle East & Africa Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
9.1.1.5 Rest of Middle East Africa
9.1.1.5.1 Overview
9.1.1.5.2 Rest of Middle East & Africa: Middle East & Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.5.3 Rest of Middle East & Africa: Middle East & Africa Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.5.3.1 Rest of Middle East Africa: Middle East & Africa Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
9.1.1.5.4 Rest of Middle East Africa: Middle East & Africa Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.5.5 Rest of Middle East & Africa: Middle East & Africa Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
10. Middle East & Africa Lung Cancer Therapy Market – Industry Landscape
10.1 Overview
10.2 Growth Strategies in Middle East & Africa Lung Cancer Therapy Market
10.3 Inorganic Growth Strategies
10.3.1 Overview
10.4 Organic Growth Strategies
10.4.1 Overview
11. Company Profiles
11.1 Medtronic Plc
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 RF Medical Co Ltd
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Johnson & Johnson
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Merck KGaA
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Sun Pharmaceutical Industries Ltd
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Bioventus Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Olympus Corp
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
12. Appendix
12.1 About Us
12.2 Glossary of Terms

LIST OF TABLES

Table 1. Middle East & Africa Lung Cancer Therapy Market Segmentation
Table 2. Middle East & Africa Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 3. Saudi Arabia: Middle East & Africa Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 4. Saudi Arabia: Middle East & Africa Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 5. Saudi Arabia: Middle East & Africa Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 6. Saudi Arabia: Middle East & Africa Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 7. South Africa: Middle East & Africa Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 8. South Africa: Middle East & Africa Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 9. South Africa Middle East & Africa Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 10. South Africa: Middle East & Africa Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 11. UAE: Middle East & Africa Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 12. UAE: Middle East & Africa Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 13. UAE: Middle East & Africa Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 14. UAE: Middle East & Africa Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 15. Rest of Middle East & Africa: Middle East & Africa Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 16. Rest of Middle East & Africa: Middle East & Africa Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 17. Rest of Middle East Africa Middle East & Africa Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 18. Rest of Middle East & Africa: Middle East & Africa Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 19. Recent Inorganic Growth Strategies in the Middle East & Africa Lung Cancer Therapy Market
Table 20. Recent Organic Growth Strategies in Middle East & Africa Lung Cancer Therapy Market
Table 21. Glossary of Terms, Middle East & Africa Lung Cancer Therapy Market

LIST OF FIGURES

Figure 1. Middle East & Africa Lung Cancer Therapy Market Segmentation, By Country
Figure 2. Middle East & Africa Lung Cancer Therapy Market – Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Middle East & Africa Lung Cancer Therapy Market Revenue (US$ Mn), 2020 – 2030
Figure 5. Middle East & Africa Lung Cancer Therapy Market Revenue Share, by Therapy Type, 2022 & 2030 (%)
Figure 6. Non-Invasive Therapy: Middle East & Africa Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Minimally Invasive: Middle East & Africa Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Middle East & Africa Lung Cancer Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
Figure 9. Non-Small Cell Lung Cancer: Middle East & Africa Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Small Cell Lung Cancer: Middle East & Africa Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Middle East & Africa Lung Cancer Therapy Market Revenue Share, End User, 2022 & 2030 (%)
Figure 12. Hospitals: Middle East & Africa Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Oncology Clinics: Middle East & Africa Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Research Centers: Middle East & Africa Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. Others: Middle East & Africa Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Middle East & Africa Lung Cancer Therapy Market, by Key Country – Revenue, 2022 (US$ Million)
Figure 17. Middle East & Africa Lung Cancer Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 18. Saudi Arabia: Middle East & Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 19. South Africa: Middle East & Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 20. UAE: Middle East & Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 21. Rest of Middle East & Africa: Middle East & Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. Growth Strategies in Middle East & Africa Lung Cancer Therapy Market

The List of Companies – Middle East & Africa Lung Cancer Therapy Market

1. Bioventus Inc
2. Johnson & Johnson
3. Medtronic Plc
4. Merck KGaA
5. Olympus Corp
6. RF Medical Co Ltd
7. Sun Pharmaceutical Industries Ltd

Reviews

There are no reviews yet.

Be the first to review “Middle East & Africa Lung Cancer Therapy Market Forecast to 2030”